Transcript PPT - Altogen Biosystems

Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products >
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
Altogen Biosystems offers the HepG2 Transfection Reagent
among a host of 100+ cell line specific In Vitro Transfection Kits.
The HepG2 Transfection Reagent is a proprietary cationic lipids
formulation that enhances lipid mediated transfection, and it has
been developed to provide high transfection efficiency with HepG2
cells.
This cell line is a good host for transfection and research related to
liver function. When cultured in vitro, HepG2 cells are a monolayer
and adhere to the surface of the culture flask.
Other applications include drug discovery, gene expression
studies, molecular and cell biology research applications.
Purchase HepG2 Transfection Kit at www.Altogen.com
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
HepG2 Cell Line Description and Applications
Products >
HepG2 Cells
Altogen.com
The HepG2 cell line originates from the a 15-year
old male patient who suffered from differentiated
hepatocellular carcinoma. The cells were taken
from liver tissue and the HepG2 cell line as well as
related derivatives can be used as a model system
for research related to liver metabolism as well as
hepatocarcinogenesis, xenobiotics toxicity, and
antigenotoxic and cogenotoxic agents. The HepG2
cell line display epithelial morphology and have a
model chromosome number of 55. The cells also
produce albumin, plasminogen, fibrinogen, alpha 2macroglobulin, alpha 1-antitrypsin, and transferrin.
Research indicates that HepG2 cells are resistant to
G418, but are responsive to human growth
hormone stimulation.
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
HepG2 Transfection Protocol
Products >
1. Plate 10,000 - 15,000 HepG2 cells per well in 0.5 ml of complete growth medium 12–24 hours prior to
transfection
2. Wash with 1xPBS and add 0.5 ml of fresh growth medium
3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent,
and
• 750 ng DNA (or mRNA), or
• 30 nM - 50 nM of siRNA (or microRNA)
*Referred to a final volume including growth medium
4. Incubate transfection complexes at RT for 15 - 30 minutes
5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex,
therefore increasing transfection efficiency; however it may increase cell toxicity
6. Add prepared transfection complexes to 0.5 ml of complete growth medium with HepG2 cells (from step
2)
7. Incubate cells at 37ºC in a humidified CO2 incubator
8. Assay for phenotype or target gene expression 48 - 72 hours after transfection
Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of
Transfection Enhancer reagent 12-24 hours after transfection
If the viability of HepG2 cells being transfected is affected at 16 - 24 hours post-transfection, the level of cytotoxicity
can be decreased by changing the growth medium and eliminating redundant exposure of cells to transfectant
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
General Lipoplex-mediated Transfection Mechanism of Action
Products >
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
HepG2 Transfection Kit Product Details
Products >
•
Proprietary cationic lipids formulation
•
Transfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA
and microRNA
•
Transfection Enhancer reagent provided with the kit
•
Produce higher level of recombinant protein expression with minimal disruption of normal
cell function
•
Generate physiologically relevant data you can trust
•
Effective for plasmid DNA/siRNA co-transfection
•
Easy-to-use transfection protocol with reproducible results
•
Low cytotoxicity
Developed and manufactured by Altogen Biosystems (www.Altogen.com)
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products >
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
Data
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the HepG2 cells transfected with
siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested
and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the
18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to
untreated sample. Data are means ± SD (n=3).
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products >
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
Data
Figure 2. Protein expression of GAPDH in HepG2 cells. DNA plasmid expressing GAPDH or siRNA targeting
GAPDH were transfected into HepG2 cells following Altogen Biosystems transfection protocol. At 72 hours posttransfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein,
10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
HepG2 Transfection Reagent (Hepatocellular Carcinoma)
HepG2 Transfection Kit Benefits
Products >
• Pre-optimized transfection protocol for HepG2 cell line
• Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing
• Free of serum and protein of animal origin
• Compatible with standard and reverse transfection methods (both protocols provided in the kit manual)
• Easy to use HepG2 transfection protocol ensures great performance with expedited experimental timeline
• Equally efficient for single or multiple transfections
• Can be used for transient transfection and development of stable HepG2 cell lines
• Bio-degradable after endocytosis
• Used for preclinical research worldwide
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]